- Confirmation
of positive proof-of-concept with lead cancer drug candidate Bria-IMT as
monotherapy demonstrates promising anti-tumor activity
- Off-the-shelf
immunotherapies provide customized, cost effective treatment options
- Positive
efficacy data with Bria-IMT was presented at a major breast cancer
conference, the 2018 San Antonio Breast Cancer Symposium
- BriaCell
Therapeutics Corp.’s poster presentation at 2018 San Antonio Breast Cancer
Symposium now available for public review
- Global
cancer immunotherapy market projected to be worth over $119 billion by
2021
Cancer patients facing limited therapeutic options are the
focus for a team of scientists and clinicians at BriaCell Therapeutics Corp.
(OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company developing
safe and effective immunotherapy treatments for advanced breast cancer
patients. BriaCell’s immunotherapy, Bria-IMT, is the company’s lead product
candidate. The company recently presented promising results for two of its
clinical studies (monotherapy and combination study of Bria-IMT with
pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]) for patients
with advanced breast cancer during the 2018 San Antonio Breast Cancer Symposium
in Texas (http://ibn.fm/0JGCl).
“I am very excited about our data continuing to show robust
biological activity of Bria-IMT™ in advanced breast cancer,” Dr. Bill Williams,
BriaCell’s president & CEO, said of the company’s presentation at the
international symposium that attracted over 7,000 academic and private
physicians and researchers (http://ibn.fm/SaO2y).
“These findings also reinforce our product development strategy for Bria-OTS™,
BriaCell’s novel off-the-shelf personalized immunotherapy, by showing
predictability of the anti-tumor responses in patients using a relatively
simple and inexpensive HLA test.”
The therapy’s mechanism of action is thought to include
providing breast cancer antigens and direct stimulation of cancer-fighting T
cells, producing anti-cancer immunity and boosting response. Bria-IMT has
demonstrated success in clinical trials, achieving proof of concept as
reflected in positive results from a Phase IIa study (http://ibn.fm/7AGpj). Results
also showed excellent tolerability and safety, demonstrating no serious side
effects for patients participating in the study.
“Based on the data of three proof of concept studies
to-date, Bria-IMT has shown the ability to produce powerful immune responses
and elicit tumor regression even in heavily pre-treated patients with very
advanced disease,” Williams added. “We are highly confident of our strategy to
use Bria-IMT in combination with KEYTRUDA®, an approved treatment for multiple
cancer indications, and expect synergistic activity of this combination in
patients with advanced breast cancer. We look forward to additional clinical
data and expect to share details at upcoming scientific meetings.”
The combination study is listed on ClinicalTrials.gov as
NCT03328026. KEYTRUDA is the Merck registered trade name of pembrolizumab.
Copies of Bria-Cell’s abstract and poster, presented in early December at the
2018 San Antonio Breast Cancer Symposium, are available now at www.BriaCell.com/Investor-Relations/Presentations.
Cancer continues to rank as the second leading cause of
death in the United States, with breast cancer being the most commonly
diagnosed cancer in women (except for skin cancers), according to the American
Cancer Society (http://ibn.fm/gMVHZ).
A report issued by MarketsandMarkets states that the global cancer
immunotherapy market is projected to reach $119.31 billion by 2021, up from
$61.9 billion in 2016 and expanding at a compound annual growth rate of 14
percent (http://ibn.fm/s55LX).
Factors such as the increasing incidence of cancer and rising health care
expenditures are driving the market’s growth, the report states.
For more information, visit the company’s website at www.BriaCell.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment